Understanding how chronic stress modulates immune activity in the tumor microenvironment



Elizabeth A. Repasky, PhD Professor of Immunology

Professor of Immunology Program Leader: *Cancer Stress Biology* Program Roswell Park Comprehensive Cancer Center Buffalo NY

AGS/NIA R13 Bench-to-Bedside Conference Series Stress Tests and Biomarkers of Resilience Hyatt Regency, Bethesda MD March 4-5, 2024

No Disclosures

Increased chronic stress in cancer patients



Systemic stress response is regulated by two major pathways



FIGHT or FLIGHT RESPONSE and psychological forms of stress (anxiety, fear, depression) including thermal stress (hot or cold)

Housing temperature: A useful model system to study the impact of <u>chronic</u> adrenergic stress on immuno-oncology

Chronic Cold Stress Standard Thermoneutral $T_a = \sim 22^{\circ}C$ $T_{a} = ~30^{\circ}C$ Thermoregulation Hypothalamus Non-Shivering Immune Activity Thermogenesis Norepinephrine **B3-Adrenergic B2-Adrenergic** Receptor Receptor

- Kokolus et al., PNAS 2013
- Eng et al., Nat Comm 2015
- Bucsek et al., Can Res 2017
- Mohammadpour et al., JCI 2019
- Chen et al., Nat Comm 2020
- Qiao et al., Can Imm Res 2021
- Mohammadpour et al., Cell Reports 2021

Figure from MacDonald/Choi et al.,/Repasky *Trends in Molec. Med.* 2023



of Laboratory Animals, 2011, National Academies Press; James et al., Temperature, 2022

We use several ways to manipulate β -AR signaling in mice



Tumor growth is slower in mice housed at 30 °C



Kokolus et al/ Repasky PNAS, 2013

N = 5 - 6; * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001

Mice Housed at TT Develop Fewer Metastatic Tumors

4T1 mouse model Triple Negative BreCa



Standard Temperature





Kokolus et al, Repasky PNAS 2013

Relief from cold stress slows tumor growth rate: *This effect is lost in SCID mice.*



Adrenergic signaling blockade improves tumor growth control at ST: depends on adaptive immune system



Propranolol: pan- β-AR antagonist

Eng et al., Nature Comm. 2015 Bucsek, Qiao et al, Cancer Research, 2017

T-cells isolated from tumors of mice housed at TT have a more "activated" phenotype



N=5/group*p<0.05

Kokolus et al, Repasky PNAS 2013

β-AR stress signaling drives CD8⁺ T cell exhaustion in the tumor microenvironment





Qiao et al., *Cancer Immunol Res*, 2021 Qiao et al., *Cancer Immunol Immunother* 2019 Inhibition of T cell function by adrenergic signaling is combined with enhanced MDSC survival and function



Hemn Mohammadpour, PhD Tumor microenvironment





Ongoing clinical translation using propranolol in combination with immuno- and/or radio-chemotherapies



New Trials Melanoma: M Myeloma: **Esophagus**:

Clinical Translation

Phase I Trial Gandhi (TII) PI Clin Can Res 2020 Multi-center Phase II Shipra Gandhi, PI Phase I/II Trial, Hillengass (PI) Phase Ib/II Singh, PI; Phase II Mukherjee, PI

Breast Cancer:

CPI refractory population: Pilot to Phase II (Gandhi, PI) seeking collaborators and funding.

Canine and Human Sarcoma: Phase II, with Cornell Univ Veterinary Hospital (in development

ICI- Bucsek et al., Cancer Res. 2017 Radiation- Chen et al., Nat. Comm, 2019 **Chemotherapies**- Eng et al., Nature Comm. 2015

SUMMARY: Chronic stress negatively influences cancer treatment outcomes through:

Suppression of anti-tumor immune activity

These data may contribute to our understanding of how chronic stress leads to more aggressive cancers in patients and to the identification of novel biomarkers in patients in need of greater stress-reducing interventions.

Question? How does chronic stress affect anti-tumor immune function in older individuals compared to those who are younger?

Whatever we accomplish is due to the combined effort." Walt Disney

Repasky Lab

Saeed Daneshmandi, PhD Sarah Choi, MSTP program Nathan Roberts, PhD student Caitlin James, PhD student Bonnie Hylander, PhD Minhui (Kate) Chen, PhD Feng Li Eugene Kononov

<u>Alumni:</u>

Hemn Mohammadpour, VDM, PhD Guanxi (Christina) Qiao, PhD Cameron MacDonald, PhD Maegan Capitano, PhD Chen-ting (Kelly) Lee, PhD Katie Kokolus, PhD Jason Eng, MD, PhD Mark Bucsek, MD, PhD

Hemn Mohammadpour Lab

Qi Yan, PhD Anushka Malhotra

Scott Abrams, PhD

Clinical collaborators

Igor Puzanov, MD Shipra Gandhi, MD Marc Ernstoff, MD Anurag Singh, MD Sarbajit Mukherjee, MD Phil McCarthy, MD

Funding Sources: NIH R01 CA205246; NIH R01 CA099326; NIH R01 CA236390; McDonald, and Mohammadpour F 30, and 32 NRSA pre- and postdoctoral fellowship (2019-2021): Mohammadpour- K99/R00 Pathway to

Independence Award (2021-2026):

RPCCC Comparative Oncology Shared Resource Sandra Sexton VDM Mike Moser, PhD (IACUC)

John Loftus, PhD Cornell Vet College Edith Lord, Scott Gerber URMC **David Farrar, PhD, UT Southwestern**MC Todd Schell, PhD; Penn State Hershey Joe Drabick MD; Penn State Hershey Andrew Lane PhD and Teresa Fan, PhD Univ. of Kentucky

Breast Cancer Coalition of Rochester, The NYS Peter T. Rowley Breast Cancer Research Grant, The Harry J. Lloyd Charitable Trust, The Roswell Park Alliance Foundation; Herd of Hope Foundation.

β2 adrenergic receptor-mediated signaling regulates the immunosuppressive potential of myeloid-derived suppressor cells <u>The Journal of Clinical Investigation</u>

Hemn Mohammadpour,¹ Cameron R. MacDonald,¹ Guanxi Qiao,¹ Minhui Chen,¹ Bowen Dong,¹ Bonnie L. Hylander,¹ Philip L. McCarthy,² Scott I. Abrams,¹ and Elizabeth A. Repasky¹ ¹Department of Immunology, and ²Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.



β2-AR signaling promotes MDSC survival & protumorigenic function

